摘要
目的 将Surodex与传统的 0 .1%地塞米松滴眼液进行比较 ,评价其用于内眼术后抗炎的有效性和安全性。方法 用健康大耳白兔制作外伤性内眼炎症模型 ,左眼在手术结束时将Surodex放入前房 ,右眼用 0 .1%地塞米松滴眼液点眼 ,观察兔眼的炎症反应及对角膜、眼压的影响 ,并检测兔眼房水中地塞米松浓度。结果 Surodex可以在术后持续、恒定地释放地塞米松 ,维持房水中 2 4h的有效药物浓度 ,而 0 .1%地塞米松在点药后 4h已低于 0 .1μg/ml。裂隙灯检查计分结果Surodex组与 0 .1%地塞米松组无显著性差异 (P >0 .0 5 ) ,与空白对照组均有显著性差异。实验组与空白对照组房水中蛋白质含量均有显著性差异 ,Surodex组与 0 .1%地塞米松组在第 3、5天有显著性差异 ,其余各天无显著性差异。各组内皮细胞活性率结果均无显著性差异 ,使用Surodex后眼压无明显变化。结论 Surodex属“零级释放系统” ,较之 0 .1%地塞米松滴眼液有显著的优越性 ,且术后抗炎与 0 .1%地塞米松滴眼液同样有效 ,甚至更佳 。
Objective To evaluate the safety of Surodex delivery system containing dexamethasone of 60μg for usage in surgery, and to compare its anti-inflammatory efficacy with conventional dexamethasone 0.1% eyedrops. Methods Fifty eyes of 25 rabbits with trauma on anterior capsular were examined. Other 10 eyes of 5 rabbits served as controls. Surodex was inserted in the anterior chamber of the left eyes of 25 rabbits at the conclusion of surgery.The right eyes received conventional 0.1% dexamethasone eyedrops four times a day for 10 days. The safety and efficacy of Surodex were evaluated by clinical slit lamp assessment, aqueous humor examination and endothelial cells count, and electrical microscope observation.Results Clinical slit-lamp assessment showed no difference between Surodex-teated eyes and dexamethasone eyedrop-treated eyes.Protein in aqueous humor had significant difference at day 3 and 5 after surgery,but showed no difference at the other days.No significant difference in endothelial cell number and morphologic observation was noted between Surodex-inserted eyes and 0.1% dexamethasone eyedrop-treated eyes.Conclusion Intraocular placement of a single Surodex is a safe and effective treatment method to reduce intraocular inflammation after anterior intraocular surgery.Surodex belongs to a typical zero-order delivery system.
出处
《江西医学院学报》
CAS
2004年第3期19-21,25,共4页
Acta Academiae Medicinae Jiangxi
